BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Association of Health Care Journalists - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Association of Health Care Journalists
X-ORIGINAL-URL:https://healthjournalism.org
X-WR-CALDESC:Events for Association of Health Care Journalists
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20140309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20141102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20150308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20151101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20160313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20161106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20151023T010000
DTEND;TZID=America/New_York:20151023T010000
DTSTAMP:20231109T162454Z
CREATED:20231103T163801Z
LAST-MODIFIED:20231109T162454Z
UID:26140-1445562000-1445562000@healthjournalism.org
SUMMARY:Drug Pricing: Public Health Implications
DESCRIPTION:Live webcast\, Oct. 23\, 12:30-1:30 p.m. ET | Watch at ForumHSPH.org\nA full course of treatment with the blockbuster Hepatitis C drug Sovaldi costs $84\,000 in the United States. A year on the new injectable cholesterol drugs Repatha and Praluent tops $14\,000. The price of new cancer drugs now averages $10\,000 per month\, according to one estimate. \nStraining under the pressure\, doctors\, patients\, and insurers are raising alarms over skyrocketing prices. Earlier this year\, the American Society of Clinical Oncology released a new “value framework” for drugs that considers health benefit and price to help guide doctor-patient conversations around treatment options. \nFor their part\, pharmaceutical companies and some economists argue that the high cost of drug development justifies the price. \nThis Forum will explore the factors driving the high cost of new drugs. What policy changes\, from the drug approval process to patent law\, could change the equation? Are some of these drugs worth the cost? And what can be done to make sure that patients can afford the medications that they need? \nParticipants  \n\n\nSteven Pearson\, President of the Institute for Clinical and Economic Review and Lecturer at Harvard Medical School \n\n\nAaron Kesselheim\, Director\, Program on Regulation\, Therapeutics\, and Law\, Brigham and Women’s Hospital\, and Associate Professor of Medicine\, Harvard Medical School \n\n\nMeredith Rosenthal\, Professor of Health Economics and Policy\, Harvard T.H. Chan School of Public Health \n\n\nLowell Schnipper\, Clinical Director\, Beth Israel Deaconess Medical Center Cancer Center\, and Chair\, American Society of Clinical Oncology’s Value in Cancer Care Task Force \n\n\nModerator : Caroline Humer\, Correspondent\, Reuters  \n\n\n Send our panelists questions in advance to theforum@hsph.harvard.edu. The Forum will accommodate as many questions as we can during a limited Q&A. \n Tweet us @ForumHSPH #MedPricing \nContact: Marge Dwyer: 617-432-8416\, mhdwyer@hsph.harvard.edu \nThe Dr. Lawrence H. and Roberta Cohn Forums at Harvard T.H. Chan School of Public Health\, presented in Collaboration with Reuters and in Association with Harvard Health Publications \n 
URL:https://healthjournalism.org/event/drug-pricing-public-health-implications/
CATEGORIES:None
END:VEVENT
END:VCALENDAR